Merck signs exclusive global license with SciBrunch for KRAS G12D drug SPR2015 in USD 2.13 billion deal
Merck signed an exclusive global license with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor. Deal grants worldwide rights to develop, manufacture, commercialize SPR2015. SciBrunch to receive USD 400 million upfront. * Milestone payments could lift total potential deal value to USD 2.13